• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias.

作者信息

Harvengt C, Heller F, Desager J P

出版信息

Artery. 1980;7(1):73-82.

PMID:7247733
Abstract

Fenofibrate, a phenoxyacid derivative, given at daily dose of 300mg during 1 year following a single blind design, lowered significantly serum triglycerides and total cholesterol in patients various types of hyperlipoproteinemias (IIa, IV, V), fibrate significantly reduced plasma uric acid. Side effects were few after prolonged treatment. Moderate and transient increases in creatine phosphokinase and glutamopyruvic transaminase values were shown in some patients. An interaction with oral anticoagulants was also observed.

摘要

相似文献

1
Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias.
Artery. 1980;7(1):73-82.
2
[The effect of fenofibrate in various types of hyperlipoproteinemias].[非诺贝特在各类高脂蛋白血症中的作用]
Lijec Vjesn. 1989 Mar;111(3):93-7.
3
[Fenofibrate, efficacy and tolerance in long-term treatment (author's transl)].非诺贝特,长期治疗中的疗效与耐受性(作者译)
Therapie. 1981 Jul-Aug;36(4):473-6.
4
[Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency].非诺贝特可增加轻度肾功能不全患者的血肌酐,但不改变其肾小球滤过率。
Nephrologie. 1999;20(1):41-4.
5
[Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)].
Nouv Presse Med. 1980 Dec 22;9(49):3759-62.
6
Changes in plasma activities of lipolytic enzymes and lipids of normolipidemic subjects given phenobarbital, a strong microsomal inducer, alone or in combination with fenofibrate.
Int J Clin Pharmacol Ther Toxicol. 1988 Mar;26(3):138-42.
7
Plasma lipid concentrations and lecithin: cholesterol acyltransferase activity in normolipidemic subjects given fenofibrate and colestipol.非诺贝特和考来烯胺治疗的血脂正常受试者的血浆脂质浓度及卵磷脂:胆固醇酰基转移酶活性
Acta Cardiol Suppl. 1981;27:103-6.
8
[The effect of fenofibrate on the lipid level in diabetic patients].非诺贝特对糖尿病患者血脂水平的影响
MMW Munch Med Wochenschr. 1983 Sep 2;125(35):751-3.
9
[Pharmacology of fenofibrate (author's transl)].非诺贝特的药理学(作者译)
Nouv Presse Med. 1980 Dec 22;9(49):3769-73.
10
[Morphometric study of hepatic peroxisomes in hyperlipoproteinemic patients treated with fenofibrate].[非诺贝特治疗的高脂蛋白血症患者肝脏过氧化物酶体的形态计量学研究]
Biomed Pharmacother. 1984;38(2):101-6.

引用本文的文献

1
OAT10/SLC22A13 Acts as a Renal Urate Re-Absorber: Clinico-Genetic and Functional Analyses With Pharmacological Impacts.OAT10/SLC22A13作为肾脏尿酸重吸收体:临床遗传学及药理学影响的功能分析
Front Pharmacol. 2022 Apr 6;13:842717. doi: 10.3389/fphar.2022.842717. eCollection 2022.
2
Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study.痛风患者与普通人群中肾结石的发病率及危险因素:一项队列研究
Arthritis Res Ther. 2017 Jul 24;19(1):173. doi: 10.1186/s13075-017-1376-z.
3
Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations.
非布司他作为一种新型强效ABCG2抑制剂的鉴定:临床应用及风险
Front Pharmacol. 2016 Dec 27;7:518. doi: 10.3389/fphar.2016.00518. eCollection 2016.
4
Targeting hypoxic response for cancer therapy.靶向缺氧反应用于癌症治疗。
Oncotarget. 2016 Mar 22;7(12):13464-78. doi: 10.18632/oncotarget.7229.
5
Fenofibrate and losartan.非诺贝特和氯沙坦。
Ann Rheum Dis. 2003 Jun;62(6):497-8. doi: 10.1136/ard.62.6.497.
6
Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.微粒化非诺贝特:其在血脂异常管理中临床疗效的最新综述
Drugs. 2002;62(13):1909-44. doi: 10.2165/00003495-200262130-00013.
7
Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.微粒化非诺贝特:其在血脂异常管理中的药效学特性及临床疗效综述
Drugs. 1997 Oct;54(4):615-33. doi: 10.2165/00003495-199754040-00007.
8
Lack of pharmacokinetic interaction of colestipol and fenofibrate in volunteers.考来替泊与非诺贝特在志愿者体内不存在药代动力学相互作用。
Eur J Clin Pharmacol. 1980 Jun;17(6):459-63. doi: 10.1007/BF00570164.
9
Effects of a salt of cholestyramine and 2-[4-(p-chlorobenzoyl)phenoxy]2-methyl propionic acid (alpha-1081) on biliary lipid secretion in rats.消胆胺与2-[4-(对氯苯甲酰基)苯氧基]-2-甲基丙酸(α-1081)的盐对大鼠胆汁脂质分泌的影响。
Br J Pharmacol. 1981 Nov;74(3):611-7. doi: 10.1111/j.1476-5381.1981.tb10471.x.
10
Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.氯贝丁酯、苯扎贝特、非诺贝特及普罗布考对血脂正常受试者血浆脂解酶的影响。
Eur J Clin Pharmacol. 1983;25(1):57-63. doi: 10.1007/BF00544015.